Spruce Biosciences (SPRB)
(Real Time Quote from BATS)
$0.47 USD
-0.01 (-1.88%)
Updated Aug 28, 2024 03:16 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Spruce Biosciences, Inc. (SPRB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.00 | $10.00 | $2.00 | 733.33% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Spruce Biosciences, Inc. comes to $4.00. The forecasts range from a low of $2.00 to a high of $10.00. The average price target represents an increase of 733.33% from the last closing price of $0.48.
Analyst Price Targets (5 )
Broker Rating
Spruce Biosciences, Inc. currently has an average brokerage recommendation (ABR) of 2.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.43 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, two are Strong Buy, representing 28.57% of all recommendations. A month ago, Strong Buy represented 28.57%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/SPRB.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 5 | 5 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.43 | 2.43 | 2.43 | 2.43 | 2.43 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/19/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Hold | Hold |
8/15/2024 | SVB Securities | Joseph P Schwartz | Hold | Hold |
8/13/2024 | Not Identified | Not Identified | Hold | Hold |
3/14/2024 | JMP Securities | Jonathan Wolleben | Strong Buy | Strong Buy |
3/14/2024 | LadenburgThalmann | Aydin Huseynov | Strong Buy | Hold |
3/14/2024 | Guggenheim Securities | Evan Wang | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.43 |
ABR (Last week) | 2.43 |
# of Recs in ABR | 7 |
Average Target Price | $4.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 253 |
Current Quarter EPS Est: | -0.27 |